Page 2 - Sell Targets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector

XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Nastassia samalGilead sciencesKey underlying holdingsHealth care select sector indexVertex pharmaceuticalsRegeneron pharmaceuticalsCardinal healthHealth care select sectorState street global advisorsSeeking alphaYear performanceFisher scientificMyers squibbCompounding healthcareSell targets

Shockwave Medical: Timing The Waves Of Opportunity (NASDAQ:SWAV)

Shockwave Medical: Timing The Waves Of Opportunity (NASDAQ:SWAV)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Technology shockwaveShockwave medical incTechnology shockwave medicalShockwave medicalIntravascular lithotripsyCompounding healthcareMedical vascular intervention overviewShockwave medical vascular intervention overviewCommon equityMedical annual revenue estimatesShockwave medical annual revenue estimatesSeeking alphaCompounding healthcare bioreactor growthMedical overviewShockwave medical overviewBuy threshold

Sangamo Therapeutics (SGMO): Ready To Start Accumulating Ahead Of A Pivotal 2023

Sangamo is making progress across their pipeline programs. Read more to see why I am willing to accumulate a hefty position in SGMO stock.

United statesFirm financialsSangamo therapeuticsMoving forward with sickle cellGlobal blood therapeuticsTherapeutics preclinical pipeline programsTherapeutics revenue estimatesSangamo therapeutics revenue estimatesSeeking alphaBuy thresholdChart enhanced viewSell targets

Collegium Pharmaceutical Q3: Changing Strategy After Earnings Beat (NASDAQ:COLL)

Collegium's new products from the BDSI acquisition have already helped it report record revenue. Read more to see my strategy to accumulate COLL stock.

United statesBiodelivery sciences internationalCollegium pharmaceuticalSell targetsCompounding healthcareNew collegiumPharmaceutical updatedCollegium pharmaceutical updatedBuy thresholdSell target

VBI Vaccines (VBIV): Recent Updates Have Fortified My Long-Term Outlook

VBI announced that Valneva will be their European partner for PreHevbrio. Read here if VBIV stock is a buy.

United kingdomCompounding healthcareOrphan drug designationCompounding healthcare bio boomBuy targetsSell targets